Anti-tumor necrosis factor drug survival in axial spondyloarthritis is independent of the classification criteria.

about

Tumor necrosis factor-α (TNFα) inhibitors in the treatment of nonradiographic axial spondyloarthritis: current evidence and place in therapy.Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study.

P2860

Q38611064-7ED41851-F660-493E-98DD-CD3524F44801 Q47100492-F6D2619C-F054-4CF0-95E3-4B025787DFFE

P2860

Anti-tumor necrosis factor drug survival in axial spondyloarthritis is independent of the classification criteria.

Item

http://www.wikidata.org/entity/Q44915013

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Anti-tumor necrosis factor dru ...... f the classification criteria.

@en

Anti-tumor necrosis factor dru ...... f the classification criteria.

@nl

type

Item

label

Anti-tumor necrosis factor dru ...... f the classification criteria.

@en

Anti-tumor necrosis factor dru ...... f the classification criteria.

@nl

prefLabel

Anti-tumor necrosis factor dru ...... f the classification criteria.

@en

Anti-tumor necrosis factor dru ...... f the classification criteria.

@nl

P1476

Anti-tumor necrosis factor dru ...... of the classification criteria

@en

P2093

Alexander K So

http://www.w3.org/2001/XMLSchema#string

Bérengère Aubry-Rozier

http://www.w3.org/2001/XMLSchema#string

Jacqueline Ghosn

http://www.w3.org/2001/XMLSchema#string

Pascal Zufferey

http://www.w3.org/2001/XMLSchema#string

P2860

Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis.

Developments in the scientific and clinical understanding of the spondyloarthritides

Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group.

A systematic MEDLINE analysis of therapeutic approaches in ankylosing spondylitis.

Spondyloarthropathies in 2010: new insights into therapy-TNF blockade and beyond.

2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis.

The frequency of non-radiographic axial spondyloarthritis in relation to symptom duration in patients referred because of chronic back pain: results from the Berlin early spondyloarthritis clinic.

Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry.

Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis.

The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection.

P2888

s00296-014-3094-z

P304

295-302

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00296-014-3094-Z

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Axel Finckh

Fabio Becce

Adrian Ciurea

P577

2014-07-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

264433396

http://www.w3.org/2001/XMLSchema#string

P698

25070142

http://www.w3.org/2001/XMLSchema#string

Anti-tumor necrosis factor drug survival in axial spondyloarthritis is independent of the classification criteria.

about

P2860

P2860

Anti-tumor necrosis factor drug survival in axial spondyloarthritis is independent of the classification criteria.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P5875

P698